Experience  /  Life Science

Representative Transactions

Represented BioMed Venture AG, a Hamburg, Germany based life science investment fund, in its investment in Intelligent Ion, Inc., a designer and manufacturer of miniaturized mass spectrometers.

Represented Tarpan Therapeutics, Inc., an early stage drug development company, in its merger with Manhattan Pharmaceuticals, Inc. (MHTT.OB).

Represented Elan Corporation, plc, a worldwide pharmaceutical and biotechnology company, in the structuring and formation of joint ventures with U.S. biotechnology companies to develop and license new drug products and technologies.

Represented Elite Pharmaceuticals, Inc. (AMEX:ELI), a pharmaceutical company principally engaged in the development of oral, controlled release products, in a generic drug development arrangement with Pliva, Inc.

Represented a private equity investor in the purchase of Class A Common Stock of AGI Genetics Incorporated Dermatics, a New York based company specializing in biomolecular research in dermatology and skin care products.

Represented Elan Corporation, plc, a worldwide pharmaceutical company, in the structuring and formation of joint ventures with U.S. pharmaceutical and biotechnology companies to develop and license new drug products and technologies.
Represented Elite Pharmaceuticals, Inc. (AMEX:ELI), a pharmaceutical company principally engaged in the development of oral, controlled release products, in a generic drug development arrangement with IntelliPharmaCeutics Corp.
Represented Elite Pharmaceuticals, Inc. (AMEX:ELI), a pharmaceutical company principally engaged in the development of oral, controlled release products, in a generic drug development arrangement with Harris Pharmaceutical, Inc. and Tish Technologies, LLC.

Represented Kali Laboratories, a developer and manufacturer of generic drugs, in the acquisition of Kali by Par Pharmaceuticals (NYSE:PRX) for $140,000,000 in cash.

Represented Zephyr Sciences, Inc. in negotiation of an exclusive worldwide licensing agreement with Xoma Ltd. (Nasdaq: XOMA) for the research, development and commercialization of products related to Xoma’s bactericidal/permeability-increasing protein (BPI), including its NEUPREX® product.